# Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)

> **NCT00822757** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 51 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Comparator: V710
- **BIOLOGICAL:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00822757
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2007-10
- **Final completion:** 2007-12
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00822757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00822757, "Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT00822757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*